Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?
Clinical Skin Cancer · 2017-12 · 2 (1-2) · 10-17
DOI: 10.1016/j.clsc.2017.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Skin Cancer, 2017-12. Verfasst von Lucas M.D. Espíndola und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Espíndola, L. M., Salhab, R. M., Anjos, C. D., Garicochea, B., & Munhoz, R. R. (2017). Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. Clinical Skin Cancer, 2(1-2), 10-17. https://doi.org/10.1016/j.clsc.2017.06.003
Vancouver
Espíndola LM, Salhab RM, Anjos CD, Garicochea B, Munhoz RR. Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. Clinical Skin Cancer. 2017;2(1-2):10-17. doi:10.1016/j.clsc.2017.06.003
BibTeX
@article{Espndola2017,
author = {Espíndola, Lucas M.D. and Salhab, Renata M. and Anjos, Carlos Dos and Garicochea, Bernardo and Munhoz, Rodrigo R.},
title = {Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?},
journal = {Clinical Skin Cancer},
year = {2017},
volume = {2},
number = {1-2},
pages = {10--17},
doi = {10.1016/j.clsc.2017.06.003}
}
EUVIMED